{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:58:40Z","timestamp":1753354720650},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.ygyno.2006.04.014","type":"journal-article","created":{"date-parts":[[2006,6,16]],"date-time":"2006-06-16T08:06:08Z","timestamp":1150445168000},"page":"637-641","source":"Crossref","is-referenced-by-count":11,"title":["Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer"],"prefix":"10.1016","volume":"103","author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet S.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2006.04.014_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2006.04.014_bib2","series-title":"Cancer: principles and practice of oncology","first-page":"1502","article-title":"Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma","author":"Ozols","year":"1997"},{"key":"10.1016\/j.ygyno.2006.04.014_bib3","series-title":"Clinical gynecologic oncology","author":"DiSaia","year":"2002"},{"key":"10.1016\/j.ygyno.2006.04.014_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum- and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2006.04.014_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/gyno.2001.6365","article-title":"Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer","volume":"83","author":"Rodriguez","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2006.04.014_bib6","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2006.04.014_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/gyno.2000.5844","article-title":"A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2006.04.014_bib8","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0090-8258(03)00470-0","article-title":"Weekly topotecan in the management of ovarian cancer","volume":"90","author":"Morris","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2006.04.014_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ygyno.2004.08.026","article-title":"Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer","volume":"95","author":"Bhoola","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2006.04.014_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0090-8258(02)00021-5","article-title":"Three consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer","volume":"88","author":"Brown","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2006.04.014_bib11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cncr.11690","article-title":"Phase II evaluation of three-day topotecan in recurrent platinum sensitive ovarian cancer","volume":"98","author":"Miller","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2006.04.014_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/gyno.2000.5902","article-title":"Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer","volume":"79","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ygyno.2006.04.014_bib13","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","article-title":"Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials","volume":"18","author":"Rustin","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2006.04.014_bib14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ygyno.2006.04.014_bib15","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2004.10.028","article-title":"Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?","volume":"22","author":"Gronlund","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806003647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806003647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T07:29:07Z","timestamp":1555658947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825806003647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0090825806003647"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2006.04.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}